Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Published:2024-06 Issue:6 Volume:25 Page:720-730
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Necchi Andrea,Roumiguié Mathieu,Kamat Ashish M,Shore Neal D,Boormans Joost L,Esen Ahmet Adil,Lebret Thierry,Kandori Shuya,Bajorin Dean F,Krieger Laurence E M,Niglio Scot A,Uchio Edward M,Seo Ho Kyung,de Wit Ronald,Singer Eric A,Grivas Petros,Nishiyama Hiroyuki,Li Haojie,Baranwal Pranshu,Van den Sigtenhorst-Fijlstra Margot,Kapadia Ekta,Kulkarni Girish S

Publisher

Elsevier BV

Reference32 articles.

1. Guideline of guidelines: non-muscle-invasive bladder cancer;Woldu;BJU Int,2017

2. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Powles;Ann Oncol,2022

3. NCCN Guidelines insights: bladder cancer, version 2. 2022;Flaig;J Natl Compr Canc Netw,2022

4. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines;Witjes;Eur Urol,2024

5. Update on the management of non-muscle invasive bladder cancer;Aldousari;Can Urol Assoc J,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer;annals of urologic oncology;2024-08-29

2. Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?;Die Urologie;2024-08-23

3. Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?;Current Opinion in Urology;2024-08-20

4. Evaluating the KEYNOTE-057 trial's findings: addressing demographic, methodological, and economic considerations;The Lancet Oncology;2024-08

5. Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?;Journal of Clinical Medicine;2024-07-14